112 results
8-K/A
EX-99.1
ATOS
Atossa Therapeutics Inc
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
7:18pm
surveillance without surgery.
Expanded access patient concluded five-years of (Z)-endoxifen treatment – the pre-menopausal, Estrogen Receptor positive … under an FDA-approved "expanded access" program completed five years of successful treatment.
Data from ongoing EVANGELINE study scheduled
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
4:00pm
without surgery.
Expanded access patient concluded five-years of (Z)-endoxifen treatment – the pre-menopausal, Estrogen Receptor positive (ER+) / Human … -approved "expanded access" program completed five years of successful treatment.
Data from ongoing EVANGELINE study scheduled to be presented
8-K
ATOS
Atossa Therapeutics Inc
12 Mar 24
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
8:30am
heads several clinical trials designed to provide patients with access to new and promising options for therapy and supportive care
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
12 Mar 24
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
8:30am
patients with access to new and promising options for therapy and supportive care.
About (Z)-Endoxifen
(Z)-endoxifen is the most active metabolite
8-K
EX-99.1
ckbq29yf5 48t
14 Aug 23
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
8:30am
8-K
EX-99.1
q0p8vcsu88x4 j3jzw
13 Aug 21
Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting
9:30am